Ejection fraction (EF) measures the amount of blood pumped out of your heart's lower chambers, or ventricles. It's the percentage of blood that leaves your ventricle when your heart contracts. The ...
Ejection fraction refers to how much blood the heart pumps out during a contraction. An abnormal ejection fraction can be a sign of heart failure. Some people might need treatment to improve their ...
Personalized gene expression profiling-guided (MAGE) therapy in resistant sarcomas. Preliminary data. This is an ASCO Meeting Abstract from the 2016 ASCO Annual Meeting I. This abstract does not ...
The role of ACE inhibitors in the management of HFPEF is less significant compared with their role in the management of heart failure with left ventricular systolic dysfunction. For patients with ...
LONDON — The benefit of mineralocorticoid receptor antagonists (MRAs) for the treatment of patients with heart failure and mildly reduced or preserved ejection fraction has finally been established in ...
Expert physicians consider how the treatment of patients differ when they have HFpEF versus HFrEF. Scott D. Solomon, MD: When we think about the standard care in heart failure, we have to make the ...
Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target ...
The EMPEROR-Reduced trial previously showed that the sodium–glucose co-transporter 2 (SGLT2) inhibitor empagliflozin reduced the risk of cardiovascular death or hospitalisation for heart failure in ...
An overview of the PARAGON-HF trial with special consideration to the rationale behind the design, the cardiovascular end points, and the safety profile. John McMurray, MBChB: The most recent attempt ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback